Susan E. Moody

Broad Institute — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

28h-index8.5kcitations114works6.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Protein Tyrosine Phosphatases(60), Melanoma and MAPK Pathways(34), Synthesis and biological activity(11), Lung Cancer Treatments and Mutations(11), Protein Kinase Regulation and GTPase Signaling(10)

Publications114 total

Abstract CT073: A first-in-human study of oral TNO155 (batoprotafib) alone and in combination with EGF816 (nazartinib) in adult patients with advanced solid tumors
Cancer Research·2025· 1 cited
A compendium of Amplification-Related Gain Of Sensitivity genes in human cancer
Nature Communications·2025· 11 citedOpen Access
A compendium of Amplification-Related Gain Of Sensitivity (ARGOS) genes in human cancer
2023· 2 citedOpen Access
CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors
Science Advances·2023· 24 citedOpen Access
Supplementary Figure 4 from SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors
2023Open Access
Supplementary Material and Methods from Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers
2023Open Access
Table S4 from Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers
2023Open Access
Supplementary Table 3 from SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors
2023Open Access
Supplementary Figure 4 from SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors
2023Open Access
Supplementary Figures from Inhibition of <i>KRAS</i>-Driven Tumorigenicity by Interruption of an Autocrine Cytokine Circuit
2023Open Access
Table S3 from Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers
2023Open Access
Figure S2 from Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers
2023Open Access
Supplementary Figure 2 from SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors
2023Open Access
Table S2 from Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers
2023Open Access
Supplementary Table 2 from SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors
2023Open Access
Table S1 from Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers
2023Open Access
Figure S4 from Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers
2023Open Access
Supplementary Figure 2 from SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors
2023Open Access
Supplementary Figure 1 from SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors
2023Open Access
Table S3 from Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers
2023Open Access
page 1 of 6Next →

Frequent Co-authors

Jeffrey A. Engelman(16), Lewis A. Chodosh(13), Morvarid Mohseni(13), Giordano Caponigro(13), Chen Liu(12), Hengyu Lu(12), Peter S. Hammerman(12), Hongyun Wang(9), William C. Hahn(8), Matthew J. LaMarche(8), Roberto Velazquez(8), Huai-Xiang Hao(7), Silvia Goldoni(7), Matthew J. Meyer(7), Tinya J. Abrams(7), Huai‐Xiang Hao(6), Robert D. Cardiff(5), George K. Belka(5), Lukas Manuel Dunkl(5), Malika Kazic-Legueux(5)